Your session is about to expire
← Back to Search
Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test (CAPTURE-2 Trial)
N/A
Waitlist Available
Led By Vicki Kalen
Research Sponsored by LumiraDx UK Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
No Placebo-Only Group
Summary
This trial evaluates how well the LumiraDx SARS-CoV-2 Ab Test works compared to the reference method.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Performance Evaluation
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: All Patients:Experimental Treatment2 Interventions
Capillary and Venous Blood Collections
Find a Location
Who is running the clinical trial?
LumiraDx UK LimitedLead Sponsor
15 Previous Clinical Trials
34,337 Total Patients Enrolled
Vicki KalenPrincipal InvestigatorEclipse Clinical Research
William SimonPrincipal InvestigatorProfessional Research Network of Kansas
2 Previous Clinical Trials
2,200 Total Patients Enrolled
Matthew MorganPrincipal InvestigatorCentura Health Physician Group
2 Previous Clinical Trials
2,200 Total Patients Enrolled
Melanie HoppersPrincipal InvestigatorPhysicians Quality Care of Jackson
1 Previous Clinical Trials
1,134 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently using or have used an experimental treatment or device in the last 30 days.
Research Study Groups:
This trial has the following groups:- Group 1: All Patients:
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.